Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 31 Aug 2017
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors AstraZeneca
- 10 Jun 2017 Biomarkers information updated
- 13 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 14 Jan 2015 Planned End Date changed from 1 Aug 2018 to 1 Apr 2020 as reported by ClinicalTrials.gov.